- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably ...

Determinants of pathological complete response and tumor regression in high-risk breast cancer treated with neoadjuvant radiotherapy and chemotherapy. This is an ASCO Meeting Abstract from the 2024 ...

HUTCHMED announced significant findings from the SACHI Phase III study, which investigated the combination of savolitinib and osimertinib in treating patients with locally advanced or metastatic EGFR ...

Food insecurity and disparities in mental health symptoms and severity among breast cancer survivors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a type of ...

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response ...

– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...

MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...

AstraZeneca presented data from the AURA3 trial that data is supportive of Tagrisso (osimertinib) potentially becoming the new standard of care for 2nd-line treatment of patients with epidermal growth ...